FLX Bio Revenue and Competitors

Claim your profile

Location

$319.7M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • FLX Bio's estimated annual revenue is currently $11.6M per year.(i)
  • FLX Bio received $60.0M in venture funding in December 2017.
  • 0
  • FLX Bio's total funding is $319.7M.

Employee Data

    00
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$27.4M177-14%$160MN/A
#2
$3.7M24N/AN/AN/A
#3
$18.1M117-4%$24.1MN/A
#4
$47.1M304-3%N/AN/A
#5
$48.1M310-7%$403MN/A
#6
$459.2M206854%$242.6MN/A
#7
$0.9M650%$6.1MN/A
#8
$14.9M96-17%$140MN/A
#9
$29M187-1%N/AN/A
#10
$3.7M24N/AN/AN/A

FLX Bio, Inc. is an immuno-oncology company focused on the discovery and development of orally-available, small molecule drugs to activate the immune system and eradicate cancer. Using its integrated immuno-oncology drug discovery platform, FLX Bio's small molecule compounds specifically target proteins and pathways important for regulatory T cells or myeloid cells within the tumor microenvironment. Its lead candidate FLX475, a best-in-class CCR4 inhibitor, entered Phase 1 studies in December 2017 and has the potential to be used alone or in combination with checkpoint inhibitors to treat a variety of cancers. The company employs a precision medicine strategy for prospective patient selection in clinical studies, applying its robust computational and translational biology capabilities to identify key biomarkers that should maximize clinical response and increase the probability of clinical success. In addition, FLX is developing small molecule inhibitors of GCN2, a stress response kinase that detects amino acid starvation in the tumor microenvironment, and USP7, a therapeutic target involved in multiple cancer pathways. Located in South San Francisco, Calif., and funded by leading investors, including The Column Group (TCG), Kleiner Perkins (KP), Topspin Partners, GV (formerly Google Ventures) and Celgene Corporation, FLX Bio has assembled a leadership team and advisory group with a proven track record of success and team of scientists with substantial knowledge and expertise in drug discovery and translational areas essential to execute on this approach. For more information, please visit www.flxbio.com.

keywords:Licensing,Biotechnology,Healthcare,Pharmaceuticals

$319.7M

Total Funding

N/A

Number of Employees

$11.6M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

FLX Bio News

2022-04-20 - Cyclin Dependent Kinase 6 Manufacturers Profiles, Market ...

... Size 2022 Segments, Competitors Strategy, Regional Analysis, Key Players |Beta Pharma Inc, Eli Lilly and Company, FLX Bio Inc, G1 Therapeutics Inc.

2022-04-20 - Cyclin Dependent Kinase 6 Market – Major Technology Giants ...

... Eli Lilly and Company, FLX Bio Inc, G1 Therapeutics Inc, Jiangsu Hengrui Medicine Co Ltd, Novartis AG, Onconova Therapeutics Inc, Pfizer Inc,...

2022-04-19 - CC Chemokine Receptor Type 4 Market Investment Analysis ...

Affitech A/S, AstraZeneca Plc, ChemoCentryx Inc, Corion Biotech Srl, FLX Bio Inc, Globavir Biosciences Inc, Kyowa Hakko Kirin Co Ltd, Ono...

2020-07-21 - FLX Distribution Closes $2.5M Seed Funding Round

FLX Distribution, a Basking Ridge, NJ-based professional network technology platform bringing together asset management firms and independent distribution professionals, closed a $2.5m seed funding round. The round was led by RiverNorth Capital Management, with participation from six strategic, ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A0N/A$155M
#2
$0.8M4N/AN/A
#3
$0.9M6-65%N/A
#4
N/A740%$35M
#5
$1M7N/AN/A

FLX Bio Funding

DateAmountRoundLead InvestorsReference
2016-04-27$50.0MBMultipleArticle
2017-12-22$60.0MCGoogle VenturesArticle